AVITA Medical to Host Investor Webinar Briefing
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AVITA Medical (NASDAQ: RCEL, ASX: AVH), a therapeutic acute wound care company, has announced an upcoming investor webinar briefing scheduled for February 18, 2025, at 2:00 p.m. Pacific Standard Time (February 19, 2025, at 9:00 a.m. Australian Eastern Daylight Time).
The presentation will be led by CEO Jim Corbett and CFO David O'Toole, focusing on the company's financial and business results from their recent fourth quarter and full-year 2024 earnings webcast. The event will include a Q&A session, with participants able to submit questions through the registration page.
Interested shareholders and prospective investors can register for the webinar via a provided Zoom link. A replay of the presentation will be made available on the AVITA Medical investor relations website.
Details
News Market Reaction – RCEL
The recorded move for RCEL in the trading session of this news was +20.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VALENCIA, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 18, 2025, at 2:00 p.m. Pacific Standard Time (February 19, 2025, at 9:00 a.m. Australian Eastern Daylight Time).
The webinar presentation will cover financial and business results from our recent fourth quarter and full-year 2024 earnings webcast and will conclude with a Q&A session. Participants are invited to submit their questions via the registration page.
To register for the presentation, please follow this Zoom link:
https://us02web.zoom.us/webinar/register/WN_Nx3kCIIOSmOj686nctwpRA.
A replay will be available on the AVITA Medical website, ir.avitamedical.com, following the presentation.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering a groundbreaking solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.